Patient characteristics
Parameter . | Patients n (%) . | Controls n (%) . |
|---|---|---|
| Total no. | 28 | 35 |
| Sex | ||
| Male | 24 (86) | 26 (74) |
| Female | 4 (14) | 9 (26) |
| Age, y, median | 48.5 | 48.8 |
| Range | 23-65 | 28-60 |
| Molecular rearrangement | ||
| bcl1 | 11 | ND |
| IgH | 9 | ND |
| Probe not available | 8 | 35 |
| Cyclin D1 expression | ||
| Positive | 18 | 19 |
| Negative | 3 | 9 |
| Not done | 7 | 7 |
| Cyclin D1 and bcl1 status | ||
| One or both markers available | 26 | 28 |
| Cyclin D1 and/or bcl1 positive | 23 (89) | 19 (68) |
| CD20+/CD5+/CD23- immunophenotype | 28 (100) | 35 (100) |
| Ann Arbor Stage III-IV | 28 (100) | 35 (100) |
| B symptoms | 11 (39) | 14 (40) |
| Mass larger than 10 cm | 8 (29) | 7 (20) |
| LDH, abnormal | 10 (36) | 9 (26) |
| IPI | ||
| 0-1 | 10 (36) | 6 (17) |
| 2-3 | 14 (50) | 27 (77) |
| 4-5 | 4 (14) | 2 (6) |
| Sites of involvement | ||
| No. of nodal sites, median, inclusive of spleen | 5.5 | 4.4 |
| Extranodal sites, exclusive of BM | 13 (46) | 17 (48) |
| BM involvement, histology | 26 (93) | 22 (62) |
| BM involvement, PCR | 20 (100*) | ND |
| Lymphoma cells in PB, immunophenotype | 16 (57) | ND |
| Lymphoma cells in PB, PCR | 20 (100*) | ND |
Parameter . | Patients n (%) . | Controls n (%) . |
|---|---|---|
| Total no. | 28 | 35 |
| Sex | ||
| Male | 24 (86) | 26 (74) |
| Female | 4 (14) | 9 (26) |
| Age, y, median | 48.5 | 48.8 |
| Range | 23-65 | 28-60 |
| Molecular rearrangement | ||
| bcl1 | 11 | ND |
| IgH | 9 | ND |
| Probe not available | 8 | 35 |
| Cyclin D1 expression | ||
| Positive | 18 | 19 |
| Negative | 3 | 9 |
| Not done | 7 | 7 |
| Cyclin D1 and bcl1 status | ||
| One or both markers available | 26 | 28 |
| Cyclin D1 and/or bcl1 positive | 23 (89) | 19 (68) |
| CD20+/CD5+/CD23- immunophenotype | 28 (100) | 35 (100) |
| Ann Arbor Stage III-IV | 28 (100) | 35 (100) |
| B symptoms | 11 (39) | 14 (40) |
| Mass larger than 10 cm | 8 (29) | 7 (20) |
| LDH, abnormal | 10 (36) | 9 (26) |
| IPI | ||
| 0-1 | 10 (36) | 6 (17) |
| 2-3 | 14 (50) | 27 (77) |
| 4-5 | 4 (14) | 2 (6) |
| Sites of involvement | ||
| No. of nodal sites, median, inclusive of spleen | 5.5 | 4.4 |
| Extranodal sites, exclusive of BM | 13 (46) | 17 (48) |
| BM involvement, histology | 26 (93) | 22 (62) |
| BM involvement, PCR | 20 (100*) | ND |
| Lymphoma cells in PB, immunophenotype | 16 (57) | ND |
| Lymphoma cells in PB, PCR | 20 (100*) | ND |
ND indicates not done; and LDH, lactate dehydrogenase
Twenty of 20 informative patients